Alkem Laboratories Limited has signed a license agreement with Harvard University’s Office of Technology Development (OTD) enabling Alkem to develop and commercialize a novel technology that may help meet the dire need for effective treatment of diabetic neuropathy, foot ulcers, peripheral arterial disease (PAD), and other injuries caused by vascular disease.
Developed in the lab of David Mooney, Ph.D. at Harvard’s Wyss Institute for Biologically Inspired Engineering and John A. Paulson School of Engineering and Applied Sciences (SEAS), the technology is an injectable, biocompatible scaffold for the sustained release of tissue-regenerative molecules.
Alkem plans to apply its drug development and manufacturing capability to advance this technology from bench to bedside through the application of efficient translational, pre-clinical, and clinical models.
The license grants Alkem commercialization rights in the United States and India.
